logo

GBIO

Generation BioยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

GBIO Profile

Generation Bio Co.

A biotechnology company that develops gene therapies for the treatment of liver and retina diseases

Pharmaceutical
10/21/2016
06/12/2020
NASDAQ Stock Exchange
115
12-31
Common stock
301 Binney Street, Cambridge, Massachusetts 02142
--
Generation Bio Co. was established on October 21, 2016. The company is an innovative genetic medicine company that leverages its proprietary non-viral gene therapy platform to create a new class of gene therapies that provide long-lasting, reusable treatments for millions of patients with rare and endemic diseases. The company's non-viral gene therapy platform integrates high-volume DNA constructs known as closed DNA or ceDNA; the company's cell-targeted lipid nanoparticle delivery system, or ctLNP; and its established, scalable capillar-free manufacturing process. The company is using the company's approach to develop new gene therapies to deliver genetic payloads to a variety of tissues, including a variety of diseases.